NVS
Price
$131.40
Change
-$0.39 (-0.30%)
Updated
Oct 21, 11:40 AM (EDT)
Capitalization
253.84B
7 days until earnings call
Intraday Buy/Sell Signals
SNYNF
Price
$100.19
Change
+$5.16 (+5.43%)
Updated
Oct 16 closing price
Capitalization
122.7B
Intraday Buy/Sell Signals
Interact to see
Advertisement

NVS vs SNYNF

Header iconNVS vs SNYNF Comparison
Open Charts NVS vs SNYNFBanner chart's image
Novartis AG
Price$131.40
Change-$0.39 (-0.30%)
Volume$500
Capitalization253.84B
Sanofi
Price$100.19
Change+$5.16 (+5.43%)
Volume$796
Capitalization122.7B
NVS vs SNYNF Comparison Chart in %
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNYNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. SNYNF commentary
Oct 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Buy and SNYNF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 21, 2025
Stock price -- (NVS: $131.79 vs. SNYNF: $100.19)
Brand notoriety: NVS and SNYNF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 104% vs. SNYNF: 15%
Market capitalization -- NVS: $253.84B vs. SNYNF: $122.7B
NVS [@Pharmaceuticals: Major] is valued at $253.84B. SNYNF’s [@Pharmaceuticals: Major] market capitalization is $122.7B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $725.2B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $94.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileSNYNF’s FA Score has 1 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • SNYNF’s FA Score: 1 green, 4 red.
According to our system of comparison, NVS is a better buy in the long-term than SNYNF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 3 TA indicator(s) are bullish while SNYNF’s TA Score has 5 bullish TA indicator(s).

  • NVS’s TA Score: 3 bullish, 5 bearish.
  • SNYNF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SNYNF is a better buy in the short-term than NVS.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +2.07% price change this week, while SNYNF (@Pharmaceuticals: Major) price change was +1.76% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.47%. For the same industry, the average monthly price growth was +2.03%, and the average quarterly price growth was +19.53%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.47% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($254B) has a higher market cap than SNYNF($123B). NVS has higher P/E ratio than SNYNF: NVS (19.21) vs SNYNF (16.69). NVS YTD gains are higher at: 40.309 vs. SNYNF (5.352). NVS has higher annual earnings (EBITDA): 22.7B vs. SNYNF (12.6B). SNYNF has more cash in the bank: 15.4B vs. NVS (7B). SNYNF has less debt than NVS: SNYNF (22.3B) vs NVS (32.6B). NVS has higher revenues than SNYNF: NVS (55.2B) vs SNYNF (45.7B).
NVSSNYNFNVS / SNYNF
Capitalization254B123B207%
EBITDA22.7B12.6B180%
Gain YTD40.3095.352753%
P/E Ratio19.2116.69115%
Revenue55.2B45.7B121%
Total Cash7B15.4B45%
Total Debt32.6B22.3B146%
FUNDAMENTALS RATINGS
NVS vs SNYNF: Fundamental Ratings
NVS
SNYNF
OUTLOOK RATING
1..100
8038
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
13100
SMR RATING
1..100
2961
PRICE GROWTH RATING
1..100
4654
P/E GROWTH RATING
1..100
4790
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNYNF's Valuation (6) in the null industry is in the same range as NVS (16) in the Pharmaceuticals Major industry. This means that SNYNF’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for SNYNF (100) in the null industry. This means that NVS’s stock grew significantly faster than SNYNF’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as SNYNF (61) in the null industry. This means that NVS’s stock grew similarly to SNYNF’s over the last 12 months.

NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as SNYNF (54) in the null industry. This means that NVS’s stock grew similarly to SNYNF’s over the last 12 months.

NVS's P/E Growth Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNYNF (90) in the null industry. This means that NVS’s stock grew somewhat faster than SNYNF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSSNYNF
RSI
ODDS (%)
Bearish Trend 1 day ago
45%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
44%
Bearish Trend 1 day ago
62%
Momentum
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
58%
MACD
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
51%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
53%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
46%
Bullish Trend 1 day ago
49%
Advances
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 16 days ago
51%
Declines
ODDS (%)
Bearish Trend 9 days ago
44%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
46%
Bearish Trend 1 day ago
63%
Aroon
ODDS (%)
Bullish Trend 7 days ago
46%
Bullish Trend 1 day ago
50%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNYNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SVXY49.581.86
+3.90%
ProShares Short VIX Short-Term Futures
VONG121.601.36
+1.13%
Vanguard Russell 1000 Growth ETF
QEMM68.130.71
+1.05%
SPDR® MSCI Emerging Mkts StratcFacts ETF
IQDF28.900.12
+0.42%
FlexShares Intl Qual Div ETF
CPSD25.640.10
+0.39%
Calamos S&P 500 Str Alt Prt ETF-Dec

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.27%
GSK - NVS
69%
Closely correlated
+0.48%
AZN - NVS
62%
Loosely correlated
-0.97%
PFE - NVS
60%
Loosely correlated
+0.73%
JNJ - NVS
54%
Loosely correlated
+0.26%
SNY - NVS
50%
Loosely correlated
-1.76%
More

SNYNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNYNF has been loosely correlated with SNY. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SNYNF jumps, then SNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNYNF
1D Price
Change %
SNYNF100%
N/A
SNY - SNYNF
37%
Loosely correlated
-1.76%
NVSEF - SNYNF
24%
Poorly correlated
-0.48%
AZN - SNYNF
23%
Poorly correlated
-0.97%
JNJ - SNYNF
22%
Poorly correlated
+0.26%
NVS - SNYNF
21%
Poorly correlated
+0.27%
More